Rhumbline Advisers Replimune Group, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Replimune Group, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 88,148 shares of REPL stock, worth $1.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

88,148

Previous 84,923 3.8%

Holding current value

$1.1 Million

Previous $764,000 26.44%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$8.09 - $11.23 $26,090 - $36,216	3,225 Added 3.8%	88,148 $966,000
Q2 2024 Aug 01, 2024	BUY	$5.01 - $9.46 $28,717 - $54,224	5,732 Added 7.24%	84,923 $764,000
Q1 2024 May 09, 2024	BUY	$6.87 - $9.31 $13,918 - $18,862	2,026 Added 2.63%	79,191 $646,000
Q4 2023 Feb 08, 2024	BUY	$6.75 - $16.18 $44,691 - $107,127	6,621 Added 9.39%	77,165 $650,000
Q3 2023 Nov 09, 2023	BUY	$15.96 - $22.18 $14,986 - $20,827	939 Added 1.35%	70,544 $1.21 Million
Q2 2023 Aug 08, 2023	SELL	$15.65 - $24.1 $59,908 - $92,254	-3,828 Reduced 5.21%	69,605 $1.62 Million
Q1 2023 May 11, 2023	BUY	$17.48 - $29.09 $188,259 - $313,299	10,770 Added 17.19%	73,433 $1.3 Million
Q4 2022 Feb 14, 2023	BUY	$17.09 - $27.91 $62,976 - $102,848	3,685 Added 6.25%	62,663 $1.7 Million
Q3 2022 Nov 10, 2022	BUY	$15.6 - $21.15 $233,547 - $316,636	14,971 Added 34.02%	58,978 $1.02 Million
Q2 2022 Aug 11, 2022	BUY	$13.32 - $19.98 $151,368 - $227,052	11,364 Added 34.81%	44,007 $769,000
Q1 2022 May 12, 2022	BUY	$15.24 - $29.75 $24,627 - $48,076	1,616 Added 5.21%	32,643 $554,000
Q4 2021 Feb 10, 2022	BUY	$25.43 - $34.25 $9,358 - $12,604	368 Added 1.2%	31,027 $841,000
Q3 2021 Nov 12, 2021	BUY	$28.98 - $39.54 $63,929 - $87,225	2,206 Added 7.75%	30,659 $909,000
Q2 2021 Aug 05, 2021	BUY	$28.5 - $39.37 $137,797 - $190,353	4,835 Added 20.47%	28,453 $1.09 Million
Q1 2021 May 06, 2021	SELL	$30.22 - $45.57 $34,299 - $51,721	-1,135 Reduced 4.59%	23,618 $721,000
Q4 2020 Feb 10, 2021	BUY	$23.5 - $52.65 $126,641 - $283,730	5,389 Added 27.83%	24,753 $944,000
Q3 2020 Nov 12, 2020	SELL	$18.85 - $27.0 $20,131 - $28,836	-1,068 Reduced 5.23%	19,364 $446,000
Q2 2020 Aug 13, 2020	BUY	$9.76 - $25.95 $48,887 - $129,983	5,009 Added 32.48%	20,432 $508,000
Q1 2020 May 06, 2020	BUY	$8.9 - $19.08 $4,672 - $10,017	525 Added 3.52%	15,423 $154,000
Q4 2019 Feb 05, 2020	BUY	$11.61 - $17.21 $4,237 - $6,281	365 Added 2.51%	14,898 $214,000
Q3 2019 Oct 23, 2019	SELL	$10.01 - $16.87 $1,351 - $2,277	-135 Reduced 0.92%	14,533 $202,000
Q2 2019 Aug 14, 2019	BUY	$12.51 - $17.28 $40,695 - $56,211	3,253 Added 28.5%	14,668 $215,000
Q1 2019 May 01, 2019	BUY	$10.26 - $16.24 $117,117 - $185,379	11,415 New	11,415 $174,000

Others Institutions Holding REPL

# of Institutions

149

Shares Held

68M

Call Options Held

52.3K

Put Options Held

80.3K

View Full List

About Replimune Group, Inc.

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $616M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

More about REPL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Replimune Group, Inc. Transaction History